Johnson & Johnson (JNJ)vsP3 Health Partners Inc (PIII)
JNJ
Johnson & Johnson
$261.62
+0.99%
HEALTHCARE · Cap: $614.36B
PIII
P3 Health Partners Inc
$11.58
+6.34%
HEALTHCARE · Cap: $2.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 6552% more annual revenue ($97.93B vs $1.47B). JNJ leads profitability with a 21.5% profit margin vs -8.6%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
PIII
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-84.8%
Fair Value
$139.37
Current Price
$261.62
$122.25 premium
Intrinsic value data unavailable for PIII.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 0.9%
3.5% revenue growth
0.0% earnings growth
Operating margin of 2.1%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : PIII
The strongest argument for PIII centers on Debt/Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : PIII
The primary concerns for PIII are Revenue Growth, EPS Growth, Operating Margin.
Key Dynamics to Monitor
JNJ profiles as a mature stock while PIII is a turnaround play — different risk/reward profiles.
PIII carries more volatility with a beta of 1.62 — expect wider price swings.
JNJ is growing revenue faster at 6.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 34/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →P3 Health Partners Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
P3 Health Partners Inc (PIII) is a forward-thinking healthcare organization dedicated to enhancing care quality and minimizing costs through innovative, data-driven methodologies. Specializing in value-based care models, the company leverages telehealth technologies and advanced analytics to deliver tailored healthcare solutions, particularly targeting underserved populations. By collaborating with community organizations and maintaining a robust network of primary care providers and specialists, PIII addresses the growing demand for efficient healthcare services. With a steadfast commitment to high-quality, cost-effective care, PIII is well-positioned to thrive in the evolving healthcare environment.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?